Open AccessCould Curcumin Gd-AuNP (Cur-Gd-AuNP) be Suitable as a Photosensitizer for Photodynamic Therapy in Alzheimer’s Disease?
Publication year - 2022
Publication title -
biointerface research in applied chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 11
ISSN - 2069-5837
DOI - 10.33263/briac132.174
Subject(s) - curcumin , photodynamic therapy , photosensitizer , dementia , medicine , disease , immunotherapy , pharmacology , chemistry , photochemistry , cancer , organic chemistry
Alzheimer's disease (AD) is a neurodegenerative disorder that is a common form of dementia for the elderly. According to the world health organization (WHO), around 55 million older adults have dementia globally. The current medication for Alzheimer's disease is a human antibody or immunotherapy, which helps to reduce beta-amyloid plaques. However, this cures the symptom but not the disease. Photodynamic therapy (PDT) might be a good choice for AD because it is non-pharmacological. With a few side effects only, especially in the usage of natural traditional Chinese medicine combined with nanotechnology, "curcumin" as a photosensitizer (PS), that enhances the efficacy of PDT. This short communication discusses the synthesis of curcumin Gd-AuNP (Cur-Gd-AuNP) and describes its application for PDT to treat AD in future development.